Hemorrhagic Complications of Dental Extractions in 181 Patients Undergoing Double Antiplatelet Therapy

Olga Olmos-Carrasco, MD, FP,* Victoria Pastor-Ramos, MD, PhD, DDS,† Rafael Espinilla-Blanco, MD, DMD,‡ Ana Ortiz-Zárate, MD, DMD,§ Irene García-Ávila, DMD, PhD, || Elías Rodríguez-Alonso, MD, DMD,¶ Rosario Herrero-Sanjuán, MD, DMD,# María-Magdalena Ruiz-García, DMD, ** Paloma Gallego-Beuter, MD, DMD, †† María-Paz Sánchez-Salgado, MD, DMD,‡‡ Ana-Isabel Terán-Agustín, MD, DMD,§§ Milagros Fernández-Behar, MD, DMD, || || and Inmaculada Peña-Sainz, MD, FP¶¶

Purpose: There is limited information on hemorrhagic complications during invasive dental procedures in patients treated with double antiplatelet therapy. The objective of this study is to assess the frequency of hemorrhagic complications of patients taking dual antiplatelet medication undergoing dental extractions.

Patients and Methods: An observational, multicenter, prospective, cohort study was performed in 11 oral and dental care units of primary care. The study sample was derived from the population of patients aged 18 years or older who were undergoing double antiplatelet therapy and presented to the oral and dental care units requiring dental extraction. Double antiplatelet therapy is the combination of 100 mg per day of acetylsalicylic acid and a second antiplatelet agent. The predictor variables were type of extraction performed, number of extracted teeth, number of extracted roots, and presence of inflammation. The primary outcome variable was intraoperative hemorrhage, and the secondary outcome variables were hemorrhage at 24 hours and hemorrhage at 10 days. First, a univariate analysis that considered all studied variables was performed. All variables with P < .25 in the univariate analysis were included in a multivariate analysis.

Results: The study included 181 patients. Light hemorrhage (<30 minutes) was observed in 165 patients (91.2%). Intraoperative hemorrhage lasted more than 30 minutes in 15 patients (8.3%) and more than 60

*Specialized in Family and Community Medicine, Health Center Jazmín, Servicio Madrileño de Salud, Madrid, Spain.

†Specialized in Stomatology and Maxillofacial Surgery, Oral and Dental Care Unit Alpes, Servicio Madrileño de Salud, Madrid, Spain.

\$Specialized in Stomatology, Oral and Dental Care Unit San Fermín, Servicio Madrileño de Salud, Madrid, Spain.

§Specialized in Stomatology, Oral and Dental Care Unit Benita de Ávila, Servicio Madrileño de Salud, Madrid, Spain.

||University degree in Odontology, Oral and Dental Care Unit Silvano II, Servicio Madrileño de Salud, and Assistant Professor, University Dentistry Clinic, "Alfonso X El Sabio" University of Madrid, Madrid, Spain.

¶Specialized in Stomatology, Oral and Dental Care Unit Dr. Cirajas I, Servicio Madrileño de Salud, and Associated Professor, Department of Stomatology, Faculty of Health Sciences, "Rey Juan Carlos" University of Madrid, Madrid, Spain.

#Specialized in Stomatology, Oral and Dental Care Unit Luis Vives, Servicio Madrileño de Salud, Madrid, Spain.

**University degree in Odontology, Oral and Dental Care Unit Daroca, Servicio Madrileño de Salud, Madrid, Spain. ††Specialized in Stomatology, Oral and Dental Care Unit Silvano I, Servicio Madrileño de Salud, Madrid, Spain.

‡‡Specialized in Stomatology, Oral and Dental Care Unit Jazmín, Servicio Madrileño de Salud, Madrid, Spain.

§§Specialized in Stomatology, Oral and Dental Care Unit Alameda, Servicio Madrileño de Salud, Madrid, Spain.

||||Specialized in Stomatology, Oral and Dental Care Unit Canal de Panamá, Servicio Madrileño de Salud, Madrid, Spain.

¶¶Specialized in Family and Community Medicine, Health Center Jazmín, Servicio Madrileño de Salud, Madrid, Spain.

Conflict of Interest Disclosures: None of the authors reported any disclosures.

Address correspondence and reprint requests to Dr Olmos-Carrasco: Calle de Belice 52, 28027 Madrid, Spain; e-mail: olga. olmos@salud.madrid.org

Received June 4 2014

Accepted August 5 2014

© 2015 American Association of Oral and Maxillofacial Surgeons 0278-2391/14/01318-4

http://dx.doi.org/10.1016/j.joms.2014.08.011

minutes in only 1 patient, whose hemorrhage was controlled by local hemostatic measures. The presence of inflammation and 3-root extractions increased the probability of hemorrhage persisting for more than 30 minutes by factors of 10 and 7.3, respectively.

Conclusions: In 8.3% of patients treated with dual antiplatelet therapy, dental extractions cause hemorrhagic complications lasting more than 30 minutes are resolved using local hemostatic measures. The results of this study support the safety of dental extraction without withdrawal double antiplatelet therapy. © *2015 American Association of Oral and Maxillofacial Surgeons*

J Oral Maxillofac Surg 73:203-210, 2015

Double antiplatelet therapy should not be prematurely stopped after an acute coronary syndrome or a stent implant because of the risk of myocardial infarction and death.¹ Numerous studies have assessed the frequency and severity of hemorrhagic complications of dental interventions in patients undergoing anticoagulant treatment, antiplatelet monotherapy, and anticoagulant-antiplatelet combination therapy.²⁻¹³ However, information on these complications in patients with double antiplatelet therapy is scarce. studies include patients with Few double antiaggregant therapy, and some have methodologic deficiencies regarding their small sample size and the bias inherent to retrospective data collection.^{5,14-16}

Despite this paucity of information, the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Physicians, American College of Surgeons, American Dental Association, National Health Service, and numerous authors recommend either maintaining double antiplatelet therapy in dental interventions and applying the necessary local hemostatic measures to control the hemorrhage or delaying the intervention until the dual therapy can be withdrawn without risk.^{1,17-26}

The purpose of this study was to address the following question: Among patients with double antiplatelet therapy, can dental extractions be carried out safely? We hypothesized that dental extractions have a low frequency of hemorrhagic complications that are resolved using local hemostatic measures. The specific aims of this study were to estimate the frequency of hemorrhagic complications in dental extractions of patients undergoing double antiplatelet therapy and to identify factors associated with an increased risk of intraoperative hemorrhage.

Patients and Methods

STUDY DESIGN

To address the research purpose, we designed and implemented an observational, multicenter, prospective, cohort study. This project was approved by the Ethics and Clinical Research Board of Hospital Ramón y Cajal and by the Central Research Committee of Primary Care of the Community of Madrid. The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients before enrollment in the study.

STUDY SAMPLE

The scope of the study included 11 oral and dental care units of primary care in the community of Madrid that serve a population of 561,603 persons aged older than 14 years. Of these, 2,170 persons (0.39%) were undergoing double antiplatelet therapy at the beginning of the study. The study sample was derived from the population of patients who were undergoing double antiplatelet therapy and presented to the oral and dental care units needing dental extraction between October 1, 2011 and December 31, 2013. Double antiplatelet therapy is the combination of 100 mg per day of acetylsalicylic acid and a second antiplatelet agent (clopidogrel, ticlopidine, prasugrel, or ticagrelor).

To be included in the study sample, patients must have been aged 18 years or older, been treated at least in the last 7 days, and consented to participate in the study. Patients were excluded as study patients if they were aged younger than 18 years, had stopped the single or double antiplatelet treatment for more than 48 hours before extraction, or refused study enrollment.

STUDY VARIABLES

The primary outcome variable was intraoperative hemorrhage. The secondary outcome variables were hemorrhage at 24 hours and hemorrhage at 10 days.

Intraoperative hemorrhage was defined as hemorrhage occurring either during the intervention or the subsequent time the patient spent under observation during the consultation. The severity of the hemorrhage was classified as a function of its duration and the measures needed to control it as follows: light hemorrhage if hemostasis was achieved in less than 30 minutes using the aforementioned protocol, moderate hemorrhage if the bleeding continued for more than 30 minutes but less than 60 minutes, intense hemorrhage if bleeding continued for more than 60 minutes, and severe hemorrhage when it required general measures and referral to a hospital. Thus hemorrhage at 24 hours and hemorrhage at 10 days were classified as absent, light, moderate, intense, or severe. Download English Version:

https://daneshyari.com/en/article/3156031

Download Persian Version:

https://daneshyari.com/article/3156031

Daneshyari.com